Sequencing New Agents in Prostate Cancer

Clinical Pearls

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses sequencing agents in prostate cancer.

• The FDA has approved 5 agents in the last 5 years, each of which extend survival by 2-5 months in patients with prostate cancer
• There remains a need to determine the appropriate sequencing of these agents
• Research is being conducted to develop a biomarker of response to hormonal therapy
• Research is being conducted in mouse models to reach an answer quickly, rather than wait for a clinical trial